The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | FIRE-4.5: FOLFOXIRI plus either bevacizumab or cetuximab in mCRC
Sebastian Stintzing, MD, Charité Universitätsmedizin Berlin, Berlin, Germany, describes the findings of the Phase II FIRE-4.5 study (NCT04034459) of FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus either bevacizumab or cetuximab as first-line treatment in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). FOLFOXIRI with bevacizumab resulted in a longer median progression-free survival (PFS) rate and a higher overall response rate (ORR), despite ORR as a primary endpoint not being met. Elderly patients and patients with right-sided colon cancers benefited from receiving FOLFOXIRI with bevacizumab the most. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
